Abstract: The present invention relates to an improved powdered polyvinyl alcohol (PVA), which can be used for pharmaceutical products, and that due to its improved properties can be better dosed during formulation processes.
Type:
Application
Filed:
May 10, 2017
Publication date:
April 18, 2019
Applicant:
MERCK PATENT GMBH
Inventors:
Dieter LUBDA, Mengyao ZHENG, Nicole DI GALLO, Anja-Nadine KNUETTEL
Abstract: The summary relates to a vitamin preparation, especially in gel form, for application to the skin, said preparation containing a physiologically and/or therapeutically effective amount of vitamin B12, a poloxamer as well as customary carrier substances for the formation of a carrier matrix.
Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
Type:
Application
Filed:
October 2, 2018
Publication date:
April 18, 2019
Applicants:
The Regents of the University of California, ALCHEMICAL RESEARCH HOLDINGS, LLC
Inventors:
Jose Manuel MEJIA ONETO, Ziyad F. AL-RASHID
Abstract: Disclosed are a translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD peptide is capable of improving the ability of a target substance to penetrate the cell membrane to thereby effectively deliver the target substance into a living body, including cells, tissue and blood. Thus, the TCTP-PTD peptide may be used for research purposes in vitro, and may be used for clinical purposes, including treatment of various diseases, delivery of contrast agents, etc., and may also be used for diagnostic purposes and in cosmetic applications.
Type:
Application
Filed:
April 6, 2017
Publication date:
April 18, 2019
Applicant:
Ewha University - Industry Collaboration Foundation
Inventors:
Kyung Lim Lee, Hea Duk Bae, Jee Hye Maeng
Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
Type:
Application
Filed:
December 18, 2018
Publication date:
April 18, 2019
Applicants:
BlinkBio, Inc., BlinkBio, Inc.
Inventors:
Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
Abstract: The present application provides bifunctional compounds of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 9 (CDK9). the present application also relates to methods for the targeted degradation of CDK9 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK9 which can be utilized in the treatment of disorders modulated by CDK9.
Type:
Application
Filed:
April 21, 2017
Publication date:
April 18, 2019
Inventors:
Nathanael S. GRAY, Tinghu ZHANG, Calla M. OLSON, Yanke LIANG, Nicholas KWIATKOWSKI
Abstract: The invention discloses a polyethylene glycol-modified angiogenesis inhibitor HM-1 and application thereof and relates to the field of polypeptide medicine. The polypeptide sequence of the present invention is mPEG-Arg-Gly-Ala-Asp-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp, and mPEG is chosen from mPEG-SC, mPEG2-NHS, mPEG-ALD or mPEG-bALD, with a molecular weight range of 500˜40000. The polypeptide has been modified by polyethylene glycol, has the capacity to inhibit vascular endothelial cell migration and integrin affinity and binding, and can be used for the prevention and treatment of tumors, various types of inflammation, and neovascular eye diseases. The polyethylene glycol-modified angiogenesis inhibitor disclosed by the present invention is prepared by a synthetic method.
Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
Abstract: Disclosed herein are compositions comprising HIV peptide vaults, which are vault particles comprising complexes of MVP proteins and one or more HIV peptides bound or genetically linked to one or more MVP proteins or packaged within the internal cavities of the vault particles and methods of using thereof.
Type:
Application
Filed:
May 1, 2017
Publication date:
April 18, 2019
Inventors:
Otto O. Yang, Leonard H. Rome, Jan Mrazek
Abstract: The present invention generally relates to methods of preventing methionine oxidation in immunoconjugates. The present invention also relates to pharmaceutical compositions of immunoconjugates in which the amount of methionine oxidation is minimized.
Type:
Application
Filed:
September 21, 2018
Publication date:
April 18, 2019
Inventors:
Michael Fleming, Amit Gangar, Nicholas C. Yoder, Chen Bai, Scott Alan Hilderbrand, Benjamin M. Hutchins
Abstract: The invention relates to IL-21, to antibodies and related fragments thereof for binding to IL-21, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular inflammation, infection and oncology.
Type:
Application
Filed:
December 15, 2015
Publication date:
April 18, 2019
Inventors:
Charles Reay Mackay, Di Yu, Remy Robert
Abstract: The present disclosure is directed to meditope-antibody covalent binding modalities that can be activated only after the meditope associates with a binding site on the meditope-enabled antibody. To this end, provided herein is a meditope engineered to contain a photoreactive functional group at one or more specific location(s) on the meditope so as not interfere with the specific noncovalent molecular interaction with the binding site on the meditope-enabled antibody, but still permits, and enhances, covalent bond formation. This methodology, with its speed, accuracy, consistency and simplicity has evident advantages for the development of antibody-drug conjugates.
Type:
Application
Filed:
February 2, 2017
Publication date:
April 18, 2019
Inventors:
Elisabeth Gardiner, Calin D. Dumitru, Michael H. Matho
Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Type:
Application
Filed:
October 12, 2018
Publication date:
April 18, 2019
Inventors:
Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI, Sahana BOSE
Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
Type:
Application
Filed:
September 26, 2018
Publication date:
April 18, 2019
Inventors:
David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
Abstract: The present invention relates to a prefunctionalized metallic nanoparticle (10) as a standardized basic building block of biofunctionalized nanoparticles (40), having a thiol-reactive metallic nanoparticle (12) that is prefunctionalized by a bifunctional molecule (20) that consists of an anchor component (22) and a short further-functionalization stub (24). Here, it is provided that the anchor component (22) comprises one or more dithiophosphate groups, and the short further-functionalization stub (24) is adapted for the attachment of a desired biofunctionalization (30) and is selected from the group consisting of i) an unmodified standardized oligonucleotide strand (26) having 2 to 18 bases for further-functionalization with biomolecules (30) having a terminal complementary strand (36) of the standardized oligonucleotide strand (26), and ii) a 2- to 18-base-long oligonucleotide strand (50; 60) that is modified with a terminal reactive group (52; 62) for biomolecules.
Abstract: Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
Abstract: The present invention relates to methods of treating neuropathy patients who have been administered a gabapentinoid. In particular, the methods involve administering a nucleic acid construct encoding human HGF proteins after discontinuing gabapentinoid. The present invention provides a novel method for a specific patient population to achieve a better therapeutic outcome by avoiding interference of therapeutic effects by gabapentinoids.
Abstract: Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.
Abstract: The present invention relates to a nanoparticle for oral gene delivery, which is a novel oral gene delivery system capable of regulating blood glucose levels in biological systems and insulin secretion in response to ingested meals. More specifically, the present invention relates to a nanoparticle for gene delivery, comprising: an ionic polymer conjugated with bile acid or a bile acid derivative; and a gene; and to a pharmaceutical composition comprising the same.
Abstract: Provided herein are novel methods for delivering recombinant adeno-associated viral (rAAV) particles to the central nervous system of a mammal (e.g., a human). In aspects, the methods involve administering rAAV particles containing a heterologous nucleic acid to the striatum and causing expression of the heterologous nucleic acid in at least the cerebral cortex and the striatum of the mammal.
Abstract: The present invention relates to an injectable composition for labeling a lesion and a method for providing information on the position of the lesion using the injectable composition. More specifically, the injectable composition for labeling a lesion according to the present invention can include a second composition comprising a biocompatible viscous material in a first composition comprising a complex containing an active ingredient to resolve a problem of rapid settling of the complex.
Abstract: This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers.
Type:
Application
Filed:
September 5, 2018
Publication date:
April 18, 2019
Inventors:
Stéphane HOHN, Andrew Lennard LEWIS, Sean Leo WILLIS, Matthew R. DREHER, Koorosh ASHRAFI, Yiqing TANG
Abstract: Provided herein is a compound useful as a magnetic resonance imaging (MRI) contrast agent and a therapeutic agent, said compound having a structure represented by: Y—X—Z wherein, X is Mn(II), and Y and Z are each independently a bisphosphonate coupled to one or more therapeutic agents. Methods of use of the compound for MRI imaging and treatment for cancer or a microbial infection are also provided.
Abstract: Compositions that include a phenol group conjugated to a lipid group to form a phenolic lipid. The lipid group may include a fluorophore and at least one lipid anchor. The lipid anchor may have a carbon number that ranges between 7 carbon atoms and 22 carbon atoms. Also, included are methods of making and using such phenolic lipids. Further included are methods of iodinating hydrophobic compounds such as phenolic lipids in aqueous based iodination protocols. Cosolvent formulations for use in such methods are also described.
Type:
Application
Filed:
March 31, 2017
Publication date:
April 18, 2019
Applicant:
University Of Cincinnati
Inventors:
Xiaoyang Qi, Koon Yan Pak, Brian D. Gray
Abstract: The present disclosure relates to a method for imaging cancer by administering to a patient a labeled chelating compound and an unlabeled chelating compound.
Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
Type:
Application
Filed:
October 12, 2018
Publication date:
April 18, 2019
Inventors:
Godfrey Jonah Anderson RAINEY, Wolfgang Walter Scholz, Ritsuko Sawada
Abstract: A system of fluid sterilization of fluid of vessel is provided, such as sterilization of ballast water for a water vessel. The system incorporates a heating section to heat pressurized fluid above prescribed thresholds for temperature, pressure, and duration (e.g., dwell time) to achieve desired levels of sterilization, including a heat exchanger to both (a) preheat fluid prior to entering the heating section and (b) cool outflow of the heating apparatus, in which fluid travels through the apparatus by operating valves forward and aft of the heating section in a controlled sequence to facilitate flow through the system while maintaining prescribed pressure and temperature profiles. The system operates within prescribed ranges of pressure and temperature to achieve the desired level of sterilization without need of maintaining a fixed temperature or a fixed pressure within any portion of the system, including the heating section.
Abstract: An assembly for smoothing and throttling a gaseous stream, which can be installed downstream of a region of discontinuity between areas of controlled outflow of the gas, includes an aerodynamic guide that is substantially teardrop-shaped. The assembly further includes at least one baffle that faces and is proximate to at least one respective surface of the aerodynamic guide. The baffle has the face directed toward the surface of the guide substantially similar in shape to that of the surface.
Abstract: The present device provides a safe, effective means of mobile ultraviolet (UV) disinfection. A control board within the main body of the device receives data from sensors that may variously measure orientation and speed of the main body as it moves along various surfaces for disinfection. In response to such data, the control board may brighten, dim, or completely shut off UV light-emitting diodes (UVLEs), both to prevent over- and under-exposure of the materials being disinfected, and to prevent a user from unsafely using the device.
Type:
Application
Filed:
October 16, 2018
Publication date:
April 18, 2019
Applicant:
Germbot, LLC
Inventors:
Patrick Flaherty, Karen Flaherty, Conor Flaherty, Bruce Winkler, Tim Bank
Abstract: An air purification composition. The air purification composition includes patchouli, lavender, lemon, lemongrass, rosewood, white camphor and tea tree. The air purification composition has the form of a fluid concentrate which can be used by itself or in combination with other ingredients. The air purification composition may be utilized in a targeted area to improve the air quality and scent of the air.
Abstract: Disclosed are an aroma diffusion module and an aroma diffusion container including the same. The aroma diffusion container according to an embodiment of the present invention includes a container body; an opening and closing unit coupled to the upper end of the container body; and an aroma diffusion module mounted in the container body, in which the aroma diffusion module includes a porous module body; a first hollow formed at one side of the module body; and a second hollow formed inside the module body, a porous aroma diffusion medium is accommodated in the first hollow, and the second hollow allows external air to be introduced into the container body through a slit of a membrane member unit.
Abstract: An ornamental including first and second elongate members, a transverse member, and a reservoir. The first elongate member having an inner side and an opposing outer side, The second elongate member having an outer side and an opposing inner side facing the inner side of the first elongate member. The transverse member having a first end connected directly to a first end of the first elongate member and a second end connected directly to a first end of the second elongate member. The reservoir affixed to the second end of the first elongate member.
Abstract: Disclosed is a containment component and a fragrant multi-layer assembly unit which may include at least three layers, namely a sheet forming a self-supporting carrier of the fragrance-emitting item, an adhesive interface and a liner, the sheet, which extends surface wise with a peripheral boundary, is made of paper, has a certain thickness or surface permeability on the front side, is adapted and designed to be impregnated therein with a fragrant fluid, includes a front forming the external face visible to the user of the fragrant multi-layer assembly unit, the fragrant fluid is received by the sheet, which in itself is a fragrance-emitting sheet, the scent of the fragrant fluid is released automatically and gradually from the fragrance-emitting sheet when the latter is placed in the ambient atmosphere.
Abstract: A method for sterilizing an ophthalmic lens with long-term inhibition against regrowth of micro-organisms includes the step of placing the ophthalmic lens in a sealed container containing a care solution. A photocatalytic agent coated in an inner surface of the container is exposed to ultraviolet light, to cause the photocatalytic agent to undergo a photocatalytic reaction under the ultraviolet light, which causes destruction of micro-organisms on the ophthalmic lens.
Abstract: One embodiment provides a method for preparing a medical product, said method comprising providing an aqueous dispersion of nanofibrillar cellulose, providing a layer of gauze, impregnating the layer of gauze with the aqueous dispersion of nanofibrillar cellulose, and dewatering the impregnated gauze, to obtain the medical product. One embodiment provides a medical product comprising a layer of gauze impregnated with nanofibrillar cellulose.
Abstract: An enzyme-degradable system for undergarments and feminine hygiene articles works to decompose the undergarments and feminine hygiene articles upon being triggered by bodily fluids, such as urine. The undergarment or feminine hygiene article comprises an absorbent core, an inner sheet of biodegradable material, and an outer sheet of biodegradable material. The core includes at least one of the following: a cellulose material, a wood pulp, a biodegradable and bioactive thermoplastic aliphatic polyester derived from renewable resources (polylactic acid plastic—PLA), and a superabsorbent polymer (SAP). The inner and outer sheets comprise a plant based cellulosic nonwoven material. The cellulose enzyme decomposes the absorbent core, the inner sheet, and the outer sheet upon contact with a bodily fluid. The cellulose enzyme may include DIS-1018 Cellulose-AN, a pH buffer, and additives. Fasteners made from a resilient, biodegradable material help secure the undergarments and feminine hygiene articles to the body.
Abstract: A method for preparing a highly elastic biodegradable three-dimensional structure and a highly elastic biodegradable three-dimensional structure obtained thereby, particularly, a method for preparing a three-dimensional structure maintains mechanical properties even after three-dimensional printing, by adding a biocompatible heat stabilizer to poly(L-lactide-co-?-caprolactone) and application of the three-dimensional structure to a scaffold for tissue engineering.
Type:
Application
Filed:
October 18, 2017
Publication date:
April 18, 2019
Applicant:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors:
Young Mee JUNG, Soo Hyun KIM, Su Hee KIM
Abstract: The invention relates to methods and compositions for use in the treatment or prophylaxis of intervertebral disc herniation in a mammal. The composition according to the invention comprises an inhibitor of T-cell activation, said inhibitor being capable of inhibiting CD28-mediated co-stimulation of T-cells. The said inhibitor of T-cell activation is preferably a protein comprising either an exact or a modified version of the extracellular domain of CTLA-4, such as abatacept, belatacept, XPro9523 and/or ASP2408.
Abstract: Provided is a use of one or more MicroRNA genes selected from miRNAs of Family Let-7, miR-21 or miR-222 in the construction of tissue engineered nerves and in the repair of peripheral nerve defects. An outer and/or internal surface or pores of a tissue engineered nerve graft are coated or adsorbed with polymeric nanomicrospheres carrying a Let-7 family miRNA inhibitor, miR-21, or miR-222, or a mimetic thereof, wherein the polymeric material is composed of biocompatible fibronectin and heparin. The regeneration of peripheral nerves and the construction of tissue engineered nerves are promoted by regulating the expression of MicroRNA genes which can effectively promote the proliferation of primary Schwann cells cultured in vitro and have an anti-apoptotic effect on neuronal cells. In-vivo test proves that bridging of the tissue engineered nerve graft can facilitate the regeneration of peripheral nerves, thus being useful in the treatment of peripheral nerve injury.
Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.
Abstract: Methods for denucleation of biological tissue. A method of denucleating biological tissue can include exposing a target tissue to at least one hyperosmotic solution and at least one hypoosmotic solution in an alternating fashion, and then applying a glutaraldehyde solution to the target tissue to fix the extracellular matrix and cytoskeleton of the target tissue.
Abstract: A method for preparing corneal tissue for applications predominantly in transplantation, and to the use of a solution for decellularizing corneal tissue.
Abstract: Compositions and methods for treating tissue are provided. The compositions may include tissue matrix derived from adipose tissue suitable for injection, small-volume implantation, or use as a soft-tissue regenerative material. Also provided are methods for producing such compositions.
Type:
Application
Filed:
October 18, 2018
Publication date:
April 18, 2019
Inventors:
Hui Xu, Carrie Fang, Mrinal Shah, Israel James Jessop
Abstract: Hydrogels and precursors deliver gels that support cell growth based on combinations of peptide derivatives. The combinations are based on two peptide derivatives; a first including an aromatic stacking ligand and a di-amino acid in which the amino acids include an aromatic ring; and a second including an aromatic stacking ligand and a dipeptide including one aromatic amino acid and another amino acid, which may be charged or polar. Aromatic amino acids include phenylalanine (F), tyrosine (Y) and tryptophan (W). Charged amino acids include positively charged amino acids arginine (R), histidine (H) and lysine (K), and negatively charged amino acids aspartic acid (D) and glutamic acid (E).
Type:
Application
Filed:
September 15, 2016
Publication date:
April 18, 2019
Inventors:
Eleanore Jane IRVINE, Mhairi Malone HARPER, Laura GOLDIE, Michael Leo CONNOLLY
Abstract: Star block copolymers having 3 to 8 arms are formed as a 3D foam scaffold having tailor-made pore sizes that mimic an actual cell size of a specific animal and/or human tissue and/or organs. The pore sizes are made within the elastomeric foams via a salt leaching process wherein a salt of a specific particle size is blended within the star block copolymers and crosslinked as by polyisocyanate compounds. Water or other suitable solvent are utilized to dissolve and leach out the salt leaving an open pore system. Animal and/or human cells are then injected into the 3D elastomeric foam scaffold that contains pendant liquid crystals on the star block copolymer whereby with the aid of nutrients, cells are formed within the pore system that are viable for at least three months. The size of the pore is predetermined to produce a desired cultured cell having a desired size.
Type:
Application
Filed:
November 1, 2017
Publication date:
April 18, 2019
Inventors:
Elda HEGMANN, Marianne E. PRÉVÔT, Torsten HEGMANN
Abstract: A medical device, a method for preparation thereof, and use thereof are provided. The medical device comprises a thermoplastic elastomer that is composed of soft segments and hard segments. The method for preparing a medical device comprising a thermoplastic elastomer, comprises forming the thermoplastic elastomer into tubing or other shapes via extrusion, molding, or coating, assembling the tubing or other shapes with other parts including: cables, coils, coated cables, or coated coils, and bonding the tubing, cables, or coils with other components including: other tubing components, cables, coils, sleeves, electrical pulse generator, defibrillation shock generator, electrodes, sensors, or drug release components. The medical device is used for correcting cardiac rhythm, defibrillating, assisting hearts, sensing, stimulating neurological systems, gastrointestinal system, or skeletomuscular tissues or organs.
Abstract: A variety of nanoparticles or microparticles may be used to treat diseases such as restenosis or blood clots. For example, a nanoparticle or microparticle may include a core having a biodegradable polymer, an exterior having hydrophilic moieties. and a therapeutic agent. The nanoparticles may include targeting moieties that target the nanoparticle or microparticle to an arterial lesion. The nanoparticle or microparticle may include an exterior shell around the core to increase stability of the nanoparticle or microparticle. The nanoparticle or microparticle may include a magnetic particle to allow targeted delivery of the nanoparticle or microparticle via a magnetic field. The nanoparticles or microparticles may be coated on a medical device, such as a catheter balloon or a stent, or may be delivered systemically or locally to patients in need thereof.